Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation & Amortization (CF) (2016 - 2025)

ImmunityBio (IBRX) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 6.6% to $3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 11.56% decrease, with the full-year FY2025 number at $15.5 million, down 11.56% from a year prior.
  • Depreciation & Amortization (CF) was $3.9 million for Q4 2025 at ImmunityBio, down from $4.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.2 million in Q4 2022 to a low of $3.0 million in Q1 2021.
  • A 5-year average of $4.2 million and a median of $4.3 million in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 60.56% in 2021, then dropped 15.94% in 2025.
  • ImmunityBio's Depreciation & Amortization (CF) stood at $3.6 million in 2021, then soared by 45.37% to $5.2 million in 2022, then dropped by 12.67% to $4.6 million in 2023, then dropped by 9.33% to $4.1 million in 2024, then dropped by 6.6% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Depreciation & Amortization (CF) are $3.9 million (Q4 2025), $4.0 million (Q3 2025), and $3.9 million (Q2 2025).